Click image to enlarge
U-PLEX Combos are multiplex assays that are related to a specific application. They have been assembled for ordering convenience. The U-PLEX CAR-T Cell Efficacy Combo 1 (human) contains assays for eight analytes related to CAR-T cell efficacy (Table 1). The assays can be used for quantitative measurements in the sample types listed in the "Specifications" tab below, and offer detection limits (LLODs) in the sub- to low pg/mL range.
Analyte | LLOD - ULOD | units |
Granzyme B | 0.10 – 750 | pg/mL |
IFN-γ | 1.7 – 17,000 | pg/mL |
IL-2 | 0.70 – 1,940 | pg/mL |
IL-6 | 0.33 – 1,980 | pg/mL |
IL-12p70 | 0.69 – 5,320 | pg/mL |
IP-10 | 0.49 – 6,000 | pg/mL |
Perforin | 1.9 – 20,000 | pg/mL |
TNF-α | 0.51 – 3,650 | pg/mL |
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
Analyte(s)
|
|
Granzyme B, IFN-γ, IL-2, IL-6, IL-12p70, IP-10, Perforin, TNF-α
|
|
Species
|
|
Human
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
SECTOR Imager 6000
,
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120
|
|
U-PLEX Group Compatibility
|
|
Immuno-Oncology Group 1
|
|
Plate Type
|
|
96-well
|
|
Sample Type
|
|
Cell Culture Supernatant, Plasma, Serum
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
Multi-Component
|
|
Schedule B Code
|
|
3822.19.0000
|
|
Product Description
|
Storage
|
Quantity per Kit
|
U-PLEX Linker Set, 8-Assay (300 µL)
|
2-8 °C
|
1 each (1 vial)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 each (1 plate size)
|
|
|
2-8 °C
|
1 vial (1 vial)
|
|
|
2-8 °C
|
1 vial (1 vial)
|
|
|
≤-70 °C
|
1 vial (1 vial)
|
|
|
2-8 °C
|
1 vial (1 vial)
|
|
U-PLEX 8-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
1 each (1 plate)
|
|
U-PLEX Stop Solution
|
2-8 °C
|
1 bottle (40 mL)
|
|
|
≤-10 °C
|
1 bottle (8 mL)
|
|
|
≤-10 °C
|
1 bottle (10 mL)
|
|
|
RT
|
1 bottle (18 mL)
|
|
Product Description
|
Storage
|
Quantity per Kit
|
U-PLEX Linker Set, 8-Assay (1.8 mL)
|
2-8 °C
|
1 each (1 vial)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
1 each (5 plate size)
|
|
|
2-8 °C
|
5 vial (1 vial)
|
|
|
2-8 °C
|
5 vial (1 vial)
|
|
|
≤-70 °C
|
5 vial (1 vial)
|
|
|
2-8 °C
|
5 vial (1 vial)
|
|
U-PLEX 8-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
5 each (1 plate)
|
|
U-PLEX Stop Solution
|
2-8 °C
|
1 bottle (40 mL)
|
|
|
≤-10 °C
|
1 bottle (40 mL)
|
|
|
≤-10 °C
|
1 bottle (50 mL)
|
|
|
RT
|
1 bottle (90 mL)
|
|
Product Description
|
Storage
|
Quantity per Kit
|
U-PLEX Linker Set, 8-Assay (1.8 mL)
|
2-8 °C
|
5 each (1 vial)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
5 each (5 plate size)
|
|
|
2-8 °C
|
25 vial (1 vial)
|
|
|
2-8 °C
|
25 vial (1 vial)
|
|
|
≤-70 °C
|
25 vial (1 vial)
|
|
|
2-8 °C
|
25 vial (1 vial)
|
|
U-PLEX 8-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
25 each (1 plate)
|
|
U-PLEX Stop Solution
|
2-8 °C
|
5 bottle (40 mL)
|
|
|
≤-10 °C
|
5 bottle (40 mL)
|
|
|
≤-10 °C
|
5 bottle (50 mL)
|
|
|
RT
|
5 bottle (90 mL)
|
|
Product Inserts
|
|
|
Datasheets
|
|
View More
|
Product Highlights
|
|
|
SDS
|
|
|
Technical Notes
|
|
|
Title
|
Journal
|
Year
|
|
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke
|
|
|
|
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
|
|
|
|
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations
|
|
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
IL-6 as a Mediator of the Association Between Traditional Risk Factors and Future Myocardial Infarction: A Nested Case-Control Study
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters